What You Should Know
- Therapeutic technology and immersive virtual healthcare platform XRHealth announced the strategic acquisition of PursueCare, a virtual behavioral health provider specializing in personalized addiction treatment for alcohol, opioids, cannabis, kratom, 7-OH, and co-occurring mental health conditions.
- The transaction includes PursueCare’s comprehensive multidisciplinary telehealth clinics alongside its two landmark, FDA-authorized prescription digital therapeutics (PDTs): RESET® and RESET-O®.
- The acquisition addresses a national public health crisis documented by SAMHSA: in 2025, 44.6 million Americans aged 12 or older had a substance use disorder (SUD), yet 89% received no substance use treatment, constrained by severe clinician shortages, rural provider deserts, societal stigma, and financial hurdles.
- The combined clinical entity bridges PursueCare’s licensed addiction physicians, psychiatric clinicians, therapists, and case managers directly into XRHealth’s spatial computing ecosystem—spanning AR/VR headsets, smartwatches, smartphones, and connected home digital devices.
Merging Spatial Immersion with Prescription Software
The integration brings together two historically distinct paradigms within digital therapeutics and behavioral telehealth into a unified care delivery model:
- Multidisciplinary Telehealth & Medication-Assisted Treatment (MAT): PursueCare delivers comprehensive virtual outpatient care for alcohol, opioids, cannabis, and emerging novel substances such as kratom and 7-hydroxymitragynine (7-OH), alongside co-occurring psychiatric conditions. Its clinical model integrates medical evaluations, evidence-based pharmacotherapy—such as transmucosal buprenorphine for opioid use disorder (OUD)—psychiatric medication management, licensed therapy, and dedicated case management navigating social determinants of health (SDOH) like housing, transportation, and judicial re-entry.
- The RESET® and RESET-O® PDT Pipeline: Originally pioneered by Pear Therapeutics before being acquired by PursueCare, both digital medical applications are formally cleared by the U.S. FDA to deliver structured, software-driven cognitive behavioral therapy (CBT) and contingency management. RESET® is indicated over a 12-week (90-day) course to increase abstinence and program retention in adult outpatient SUD populations, while RESET-O® provides an 84-day adjunct CBT regimen alongside buprenorphine to drive outpatient retention in adult OUD. By securing these assets, XRHealth equips clinicians to prescribe regulated, reimbursable software modules that patients practice asynchronously between live visits.
PursueCare’s clinical caseload will integrate into XRHealth’s virtual reality platform, which utilizes avatar-based group therapy rooms. Immersive spatial environments allow patients to participate in peer recovery circles and group counseling with anonymity, directly mitigating the privacy concerns and social stigma that often depress participation in traditional community support groups.
“Substance use disorders require care that is personalized, continuous, and accessible, yet too often patients face barriers to receiving the right support at the right time. The acquisition of PursueCare brings together two complementary approaches to healthcare delivery, combining PursueCare’s expertise in virtual addiction treatment with XRHealth’s technology-driven approach to personalized care. Together, we are expanding our connected healthcare ecosystem to address a broader range of conditions and give patients greater flexibility in how and where they receive care. For instance, someone struggling with an addiction can access care at the exact moment of need to prevent a further relapse. Our vision is to make personalized healthcare more accessible and seamlessly connected across the digital devices people use every day,” said Eran Orr, Founder and CEO of XRHealth.
